Precision Diagnosis and Treatment for Cancer

Optimizing therapy regimen and companion diagnostics for multiple solid tumors     
Indications: all targeted therapies for solid tumors

Relationship between cancer treatment and genetic testing

Cancer fundamentally is a genetic disease.

Therefore, tumor treatment can start from treating relevant genetic defects, affecting the characteristics of the tumor to achieve treatment. Studying cancer driver genes can indicate tumor progression, prognosis, recurrence and metastasis risk. Studying drug-related genes can guide targeted therapies and the sensitivity or resistance to certain drugs, etc. Understanding the genome of tumor is the start of of an effective treatment of cancer and can help achieve more precision treatment and maximize the clinical benefits.

Challenges of tumor precision diagnosis --- multitarget detection and combination treatment

  • Development of multi-dimensional auxiliary diagnostic system and real-world study

  • Non-invasive, continuous, real-time monitoring of molecular marker system and technology platforms

  • Liquid biopsy is one of the most effective ways to solve this problem

Liquid biopsy application

Growth and apoptosis of tumor cells are faster than normal cells; therefore there are greater amount of cell-free DNA(cfDNA) from tumor cells (ctDNA) existing in the peripheral blood of tumor patients. Genetic testing of these ctDNA will help guide cancer treatment

In the past 20 years, cancer has been redefined as a disease of genome.

Advantages and Characteristics

—— Solid tumor medication

Baishibo uses peripheral blood or tumor tissue samples for tumor related gene testing based on next generation sequencing. It helps to determine the sensitivity of targeted and chemotherapeutic drugs based on clinical evidence. The test covers all genes related to targeted therapies and chemotherapies approved by CFDA or FDA, drug-related genes evidenced by clinical trials and other cancer driver mutations. Baishibo provides patients with accurate, real-time and comprehensive information to guide treatments.

Reporting:

Genes associated with all targeted therapies and for pharmacogenetics of chemotherapy drugs approved and listed by CFDA and FDA (162 targets and 95 chemotherapeutics)

Driver gene mutations of various cancer types (Gene is various by cancer type)

Baishibo panel advantages:

Genecast focuses on individualized cancer treatment, based on publications, public database and proprietary internal database combined with meta analysis and attention to racial and ethnic differences

Genecast's gene panels specifically traget Chinese population (lung cancer, colorectal cancer, gastric cancer, liver cancer, esophageal cancer, endometrial cancer, ovarian cancer, cervical cancer, breast cancer, carcinoma tubae, malignocytoma of the head and neck and bladder cancer). And the panels are validated through a large number of samples with different cancer types.

Through detection and quantifications of different mutations, Genecast's results directly guide use of immune oncology drugs, targeted therapy drugs and chemotherapy drugs, and help to monitor cancer progressionthrough multifaceted data analysis and facilitate decisions on radiotherapy, surgery, etc..

  • Noninvasive

    Non-invasive liquid biopsy screen drug-related gene

    Provide test for patients whose tissue samples hard to obtain

  • Precision

    Precisely interpret genetic variations for drug efficacy

    Provide deep sequencing of hotspots, rare unknown mutations

  • Real time

    Provide real-time genetic profiling

    Adjust treatment accordingly

  • Comprehensiveness

    Liquid biopsy overcomes the issue withtumor tissue heterogeneity

    Reflect comprehensive tumor genetic mutation profile

Product Inspection Process:

Case I

 

Case II

Suite 903-908, HealthWork, No. 35 Huayuan North Rd., Haidian District, Beijing

info@genecast.com.cn

Follow WeChat public accounts and learn More

Copyright © 2014-2019 臻和(北京)科技有限公司 Genecast Biotechnology Co., Ltd. Design by Bobrand